PMV Pharmaceuticals Completes PYNNACLE Ovarian Cancer Enrollment
PRINCETON, N.J., Aug. 14, 2026 PMV Pharmaceuticals, Inc. reported continued progress in its Phase 2 PYNNACLE clinical trial evaluating...
Ovarian Cancer
Advertisement
BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
IMPACT Therapeutics Licenses Senaparib to Pharmanovia
SHANGHAI, July 31, 2026 IMPACT Therapeutics announced an exclusive licensing agreement with Pharmanovia, granting the global specialty pharmaceutical company...
Pheast Therapeutics Publishes New PHST001 Oncology Research
REDWOOD CITY, Calif., July 21, 2026 Pheast Therapeutics announced the publication of peer-reviewed preclinical data in Clinical Cancer Research,...
GSK Seeks EMA Approval for Bexsero Booster Vaccine Update
LONDON, United Kingdom, July 20, 2026 GSK plc has announced that the European Medicines Agency (EMA) has accepted its...
Advertisements
BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
Zentalis to Present Azenosertib Data at ESMO 2026
San Diego, California, USA | July 17, 2026 Zentalis Pharmaceuticals announced that it will present new clinical data for...
Anixa Biosciences Advances Ovarian Cancer CAR-T to Highest Dose
SAN JOSE, California, July 6, 2026 Anixa Biosciences, Inc. and Moffitt Cancer Center have announced a significant milestone in...
92Bio Doses First Patient in Phase 1 Trial of NTB-928 for Platinum-Resistant Ovarian Cancer
SAN DIEGO, Calif., July 1, 2026 92Bio, Inc. announced that the first patient has been dosed in its Phase...
Anixa Biosciences Reports Positive Phase 1 Cancer Vaccine Data
June 26, 2026 | San Jose, California, USA Anixa Biosciences, Inc. announced encouraging clinical updates from its two leading...
Advertisement
